Outcomes of advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy (original) (raw)
Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study
Munlima Hazarika
Indian Journal of Medical and Paediatric Oncology, 2015
View PDFchevron_right
A prospective comparison of perioperative morbidity in advanced epithelial ovarian cancer: Primary versus interval cytoreduction - experience from India
K Pavithran
South Asian journal of cancer
View PDFchevron_right
Role of Neoadjuvant Chemotherapy (NACT) Followed by Surgical Cytoreduction in Advanced Epithelial Ovarian Cancer
Vinod Raina
The Journal of Obstetrics and Gynecology of India, 2012
View PDFchevron_right
Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?
pravesh Dhiman
South Asian Journal of Cancer
View PDFchevron_right
Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer
Mete Güngör
Archives of Gynecology and Obstetrics, 2013
View PDFchevron_right
Integration of Neoadjuvant Chemotherapy and Interval Debulking Surgeries in Patients with Advanced Epithelial Ovarian Cancer
Loaie El-Helw
View PDFchevron_right
A New Paradigm in Managing Advanced Ovarian Cancer: Differentiating Patients Requiring Neoadjuvant Treatment from Primary Cytoreduction
Marie-Cécile Le Deley
Cancers
View PDFchevron_right
Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer
Ido Laskov
Gynecologic oncology, 2017
View PDFchevron_right
Neoadjuvant Versus Adjuvant Chemotherapy in Advanced Ovarian Carcinoma ministry of interior, Egypt
Fortune Journals
View PDFchevron_right
Interval debulking Surgery after Neoadjuvant Chemotherapy for Advanced Ovarian Carcinoma, Impact on Patients’ Survival
Sara Darwish
Ain Shams Journal of Surgery
View PDFchevron_right
Neoadjuvant Versus Adjuvant Chemotherapy in Advanced Ovarian Carcinoma
Hanan Ramadan
Journal of Cancer Science and Clinical Therapeutics, 2020
View PDFchevron_right
The Impact of Number of Cycles of Neoadjuvant Chemotherapy on Survival of Patients Undergoing Interval Debulking Surgery for Stage IIIC-IV Unresectable Ovarian Cancer: Results From a Multi-Institutional Study
stefania perotto
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2017
View PDFchevron_right
A Predictive Score after Neoadjuvant Chemotherapy for Optimal Cytoreduction at Interval Debulking Surgery in Advanced Epithelial Ovarian Cancer
Sharmin Lima
Bangladesh Medical Research Council Bulletin
View PDFchevron_right
Neoadjuvant Chemotherapy (NACT) In Advanced Epithelial Ovarian Cancer: A Review
IJAERS Journal
View PDFchevron_right
Outcomes of advanced epithelial ovarian cancer with integration of metronomic chemotherapy: An Indian rural cancer centre experience
Nilesh Sable
South Asian Journal of Cancer, 2016
View PDFchevron_right
Primary debulking surgery versus neo-adjuvant chemotherapy in stage III/IV ovarian cancer: Comparison of perioperative morbidity and survival data in Pakistani women
Aliya Aziz
2015
View PDFchevron_right
Interval Debulking Surgery (IDS) in Advanced Ovarian Cancer – Immediate Surgical Outcomes and Optimal Cytoreduction Rate
International Journal of Science and Healthcare Research (IJSHR)
https://ijshr.com/IJSHR\_Vol.5\_Issue.2\_April2020/IJSHR\_Abstract.0027.html, 2020
View PDFchevron_right
To compare the optimal cytoreduction rate in advanced epithelial ovarian cancer stage III/IV after 3 versus 6 cycles of neoadjuvant chemotherapy
monika thakur
Journal of Obstetrics and Gynaecology, 2020
View PDFchevron_right
Effect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer
Alejandra Martinez
Journal of Gynecologic Oncology, 2021
View PDFchevron_right
Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer—A National Cancer Database Study
Gary Leiserowitz
International Journal of Gynecological Cancer
View PDFchevron_right
Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV)
Dan-arin Silasi
Journal of Surgical Oncology, 2013
View PDFchevron_right
Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer
Juan Carlos Vargas Siordia
Annals of Surgical Oncology, 2016
View PDFchevron_right
Neoadjuvant chemotherapy versus primary surgery in advanced stage ovarian cancer Published paper.docx
Azza Zulfu
View PDFchevron_right
Neoadjuvant Chemotherapy Reduces the Treatment-free Interval After First-line Treatment in Patients With Advanced Ovarian Cancer
Svend Engelholm
Anticancer Research, 2020
View PDFchevron_right
Histologic parameters predictive of disease outcome in women with advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy
Nicole Turner
Translational oncology, 2012
View PDFchevron_right
Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer
Annekathryn Goodman
Annals of Surgical Oncology, 2012
View PDFchevron_right
The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer
Ahmed Zeeneldin
Archives of gynecology and obstetrics, 2017
View PDFchevron_right
Neo-adjuvant Chemotherapy Followed by Interval Debulking Surgery Versus Upfront Surgery Followed by Chemotherapy in Advanced Epithelial Ovarian Carcinoma
Mahmoud Meleis
Indian Journal of Gynecologic Oncology, 2016
View PDFchevron_right
Primary Cytoreductive Surgery Versus Interval Debulking Surgery Following Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer: An Institutional Review
Amar jain
Indian Journal of Gynecologic Oncology, 2019
View PDFchevron_right
Neoadjuvant Chemotherapy Followed by Surgery versus Primary Surgery in Advanced Epithelial Ovarian Cancer: A Review of Outcomes at National Institute of Cancer Research Hospital in Bangladesh
Annekathryn Goodman
Journal of Cancer Therapy, 2021
View PDFchevron_right
Neoadjuvant chemotherapy versus primary surgery for advanced-stage ovarian cancer: the question remains opened
Ahmed Setit
Gynecologic Oncology, 2004
View PDFchevron_right
Interval debulking surgery in advanced epithelial ovarian cancer
Franco Odicino
Best Practice & Research Clinical Obstetrics & Gynaecology, 2002
View PDFchevron_right
The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma
Curt Burger
BJOG: An International Journal of Obstetrics & Gynaecology, 2009
View PDFchevron_right
Neoadjuvant Chemotherapy Is the Better Treatment Option in Some Patients With Stage IIIc to IV Ovarian Cancer
Thomas G Ehlen
Journal of Clinical Oncology, 2011
View PDFchevron_right
Examining Survival Outcomes of 852 Women With Advanced Ovarian Cancer: A Multi-institutional Cohort Study
Jacob McGee
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2018
View PDFchevron_right